|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AKIP1 |
Gene summary for AKIP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AKIP1 | Gene ID | 56672 |
| Gene name | A-kinase interacting protein 1 | |
| Gene Alias | BCA3 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9NQ31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56672 | AKIP1 | LZE4T | Human | Esophagus | ESCC | 3.82e-09 | 3.07e-01 | 0.0811 |
| 56672 | AKIP1 | LZE7T | Human | Esophagus | ESCC | 2.34e-14 | 8.65e-01 | 0.0667 |
| 56672 | AKIP1 | LZE20T | Human | Esophagus | ESCC | 3.44e-03 | 2.33e-01 | 0.0662 |
| 56672 | AKIP1 | LZE24T | Human | Esophagus | ESCC | 2.29e-43 | 1.49e+00 | 0.0596 |
| 56672 | AKIP1 | LZE21T | Human | Esophagus | ESCC | 2.20e-05 | 5.10e-01 | 0.0655 |
| 56672 | AKIP1 | LZE6T | Human | Esophagus | ESCC | 9.72e-05 | 2.88e-01 | 0.0845 |
| 56672 | AKIP1 | P2T-E | Human | Esophagus | ESCC | 9.98e-19 | 3.80e-01 | 0.1177 |
| 56672 | AKIP1 | P4T-E | Human | Esophagus | ESCC | 5.09e-33 | 8.20e-01 | 0.1323 |
| 56672 | AKIP1 | P5T-E | Human | Esophagus | ESCC | 5.66e-16 | 3.87e-01 | 0.1327 |
| 56672 | AKIP1 | P8T-E | Human | Esophagus | ESCC | 8.58e-10 | 2.27e-01 | 0.0889 |
| 56672 | AKIP1 | P9T-E | Human | Esophagus | ESCC | 4.32e-30 | 7.32e-01 | 0.1131 |
| 56672 | AKIP1 | P10T-E | Human | Esophagus | ESCC | 4.20e-30 | 5.44e-01 | 0.116 |
| 56672 | AKIP1 | P11T-E | Human | Esophagus | ESCC | 5.12e-16 | 6.36e-01 | 0.1426 |
| 56672 | AKIP1 | P12T-E | Human | Esophagus | ESCC | 1.92e-40 | 8.82e-01 | 0.1122 |
| 56672 | AKIP1 | P15T-E | Human | Esophagus | ESCC | 7.86e-21 | 5.32e-01 | 0.1149 |
| 56672 | AKIP1 | P16T-E | Human | Esophagus | ESCC | 1.50e-16 | 1.91e-01 | 0.1153 |
| 56672 | AKIP1 | P17T-E | Human | Esophagus | ESCC | 3.79e-12 | 5.96e-01 | 0.1278 |
| 56672 | AKIP1 | P19T-E | Human | Esophagus | ESCC | 5.91e-13 | 8.61e-01 | 0.1662 |
| 56672 | AKIP1 | P20T-E | Human | Esophagus | ESCC | 2.99e-23 | 5.75e-01 | 0.1124 |
| 56672 | AKIP1 | P21T-E | Human | Esophagus | ESCC | 1.10e-26 | 5.93e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
| GO:003444620 | Esophagus | ESCC | substrate adhesion-dependent cell spreading | 65/8552 | 108/18723 | 1.67e-03 | 7.72e-03 | 65 |
| GO:00380615 | Esophagus | ESCC | NIK/NF-kappaB signaling | 81/8552 | 143/18723 | 5.33e-03 | 2.00e-02 | 81 |
| GO:003158912 | Liver | Cirrhotic | cell-substrate adhesion | 128/4634 | 363/18723 | 4.10e-06 | 6.90e-05 | 128 |
| GO:003444612 | Liver | Cirrhotic | substrate adhesion-dependent cell spreading | 47/4634 | 108/18723 | 1.48e-05 | 2.05e-04 | 47 |
| GO:1901222 | Liver | Cirrhotic | regulation of NIK/NF-kappaB signaling | 46/4634 | 112/18723 | 1.03e-04 | 1.06e-03 | 46 |
| GO:0038061 | Liver | Cirrhotic | NIK/NF-kappaB signaling | 54/4634 | 143/18723 | 3.64e-04 | 3.07e-03 | 54 |
| GO:003444622 | Liver | HCC | substrate adhesion-dependent cell spreading | 67/7958 | 108/18723 | 3.24e-05 | 3.28e-04 | 67 |
| GO:003158922 | Liver | HCC | cell-substrate adhesion | 188/7958 | 363/18723 | 2.00e-04 | 1.55e-03 | 188 |
| GO:00380611 | Liver | HCC | NIK/NF-kappaB signaling | 77/7958 | 143/18723 | 3.98e-03 | 1.76e-02 | 77 |
| GO:19012221 | Liver | HCC | regulation of NIK/NF-kappaB signaling | 60/7958 | 112/18723 | 1.17e-02 | 4.28e-02 | 60 |
| GO:003158917 | Oral cavity | OSCC | cell-substrate adhesion | 193/7305 | 363/18723 | 2.48e-08 | 4.82e-07 | 193 |
| GO:00380614 | Oral cavity | OSCC | NIK/NF-kappaB signaling | 78/7305 | 143/18723 | 1.14e-04 | 8.35e-04 | 78 |
| GO:003444618 | Oral cavity | OSCC | substrate adhesion-dependent cell spreading | 59/7305 | 108/18723 | 7.01e-04 | 3.89e-03 | 59 |
| GO:19012224 | Oral cavity | OSCC | regulation of NIK/NF-kappaB signaling | 59/7305 | 112/18723 | 2.25e-03 | 1.00e-02 | 59 |
| GO:190122212 | Oral cavity | LP | regulation of NIK/NF-kappaB signaling | 44/4623 | 112/18723 | 4.38e-04 | 4.19e-03 | 44 |
| GO:003806112 | Oral cavity | LP | NIK/NF-kappaB signaling | 52/4623 | 143/18723 | 1.20e-03 | 9.66e-03 | 52 |
| GO:003158918 | Oral cavity | LP | cell-substrate adhesion | 111/4623 | 363/18723 | 5.94e-03 | 3.53e-02 | 111 |
| GO:003444619 | Oral cavity | LP | substrate adhesion-dependent cell spreading | 38/4623 | 108/18723 | 9.38e-03 | 4.99e-02 | 38 |
| GO:003158926 | Skin | cSCC | cell-substrate adhesion | 130/4864 | 363/18723 | 1.87e-05 | 2.23e-04 | 130 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AKIP1 | SNV | Missense_Mutation | novel | c.17N>T | p.Ala6Val | p.A6V | Q9NQ31 | protein_coding | tolerated_low_confidence(0.37) | benign(0.035) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| AKIP1 | SNV | Missense_Mutation | c.224N>C | p.Arg75Thr | p.R75T | Q9NQ31 | protein_coding | tolerated(0.06) | possibly_damaging(0.836) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| AKIP1 | SNV | Missense_Mutation | c.260N>C | p.Arg87Thr | p.R87T | Q9NQ31 | protein_coding | tolerated(0.08) | possibly_damaging(0.836) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| AKIP1 | SNV | Missense_Mutation | c.554N>T | p.Gly185Val | p.G185V | Q9NQ31 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AKIP1 | SNV | Missense_Mutation | novel | c.340N>G | p.Thr114Ala | p.T114A | Q9NQ31 | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| AKIP1 | SNV | Missense_Mutation | novel | c.10N>G | p.Cys4Gly | p.C4G | Q9NQ31 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.518) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AKIP1 | SNV | Missense_Mutation | novel | c.133N>A | p.Pro45Thr | p.P45T | Q9NQ31 | protein_coding | deleterious(0.01) | benign(0.307) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| AKIP1 | SNV | Missense_Mutation | rs371516259 | c.276N>A | p.Phe92Leu | p.F92L | Q9NQ31 | protein_coding | deleterious(0.04) | benign(0.352) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| AKIP1 | SNV | Missense_Mutation | novel | c.539N>C | p.Tyr180Ser | p.Y180S | Q9NQ31 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DD-AACX-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| AKIP1 | SNV | Missense_Mutation | novel | c.335G>T | p.Gly112Val | p.G112V | Q9NQ31 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-43-8118-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |